Companies ›Healthcare ›IBRX.O

IBRX.O — NASDAQ Pharmaceuticals & Medical Research

Ibrx.O

$7,41

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

7,8B USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-226,0 %

ROE

70,2 %

Net margin

-310,2 %

Debt / equity

-1,61

Beta

—

52w range

—

Volume

Day range

—

Prev close

$7,89

Open

$7,89

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

IBRX.O is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.

Business. IBRX.O is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, with no specific operating segments or geographic breakdowns provided in the available data. Headquarters location and primary exchange listing details are not specified in the source information.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

BUY5 analysts

5 buy0 hold0 sell

Avg 12m price target14,80

Analyst recommendations

5 analysts · consensus Buy

Buy5

Hold0

Sell0

12-month price target

14,80

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

5 analysts · indicative

Ownership→

State Street Investment Management (US)

largest disclosed fund holder

Profitability→

70,2 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning IBRX.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to IBRX.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

IBRX.O is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, with no specific operating segments or geographic breakdowns provided in the available data. Headquarters location and primary exchange listing details are not specified in the source information.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

AI synthesis

GENERATED

IBRX.O has a market capitalization of $8.2 billion and a negative net income of $351.4 million, indicating a significant financial loss. The company's liquidity position is characterized by a current ratio of 5.1, suggesting strong short-term liquidity, but its total liabilities exceed total assets, resulting in a negative total equity of $500.5 million. The company's debt-to-equity ratio is -1.61, reflecting a high level of leverage and financial risk.

The company's profitability is weak, with a negative operating income of $256 million and a net loss of $351.4 million. Its return on equity is 0.7021, which is low, and its return on assets is -0.7001, indicating poor asset utilization and profitability. These metrics are below the industry median for biotechnology companies, which typically have higher returns on equity and assets.

IBRX.O's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to mitigate revenue volatility. The company's capital expenditures are relatively low at $4.25 million, suggesting a conservative approach to investment in new projects or facilities.

The company's growth trajectory is uncertain, with a negative operating cash flow of $304.9 million and a free cash flow of $342.3 million. These figures indicate that the company is not generating sufficient cash to sustain operations or fund growth initiatives. The company's revenue has not shown significant growth in recent periods, and there are no clear indicators of future revenue expansion.

The company faces several risk factors, including a high level of debt and a negative net income. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential difficulties in meeting short-term obligations. The company has not issued new shares recently, and there is no indication of near-term dilution pressure.

Recent events, including analyst estimates and price targets, suggest a mixed outlook for the company. The mean price target is $14.80, with a median of $13.00, indicating a potential for stock price appreciation. However, the company's financial performance and risk profile suggest that this appreciation may be speculative rather than based on strong fundamentals.

Key takeaways

IBRX.O has a negative net income and a high debt-to-equity ratio, indicating significant financial risk.
The company's liquidity position is strong in the short term but weak in the long term due to negative net equity.
IBRX.O's profitability metrics are below industry medians, suggesting poor performance relative to peers.
The company's revenue is not diversified across segments or geographies, increasing exposure to market-specific risks.
Analysts have a mixed outlook, with a mean price target of $14.80, but the company's financial fundamentals do not support this optimism.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$7,41

Market cap

$8.20B

Enterprise valueⓘ

$8.92B

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

-$500.5M

Net cashⓘ

-$715.1M

Current ratioⓘ

5.1

Debt / equityⓘ

-1.6

ROAⓘ

-70.0%

ROEⓘ

70.2%

Cash conversionⓘ

87.0%

CapEx / revenueⓘ

-3.8%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships18 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries18

EX21:11f501716c06EX21:11f501716c06Subsidiarie97%

EX21:261dca077b62EX21:261dca077b62Subsidiarie97%

EX21:35076f03cba5EX21:35076f03cba5Subsidiarie97%

EX21:3726b1919f10EX21:3726b1919f10Subsidiarie97%

EX21:3d5e6669c1f9EX21:3d5e6669c1f9Subsidiarie97%

EX21:4c9c0f04d8cbEX21:4c9c0f04d8cbSubsidiarie97%

EX21:59a262f4cbdcEX21:59a262f4cbdcSubsidiarie97%

EX21:61dbada0db56EX21:61dbada0db56Subsidiarie97%

EX21:703531a647beEX21:703531a647beSubsidiarie97%

EX21:73bb31b318dcEX21:73bb31b318dcSubsidiarie97%

EX21:87b8e3ef13a2EX21:87b8e3ef13a2Subsidiarie97%

EX21:ae4e06eb61edEX21:ae4e06eb61edSubsidiarie97%

EX21:c9c4d14ad266EX21:c9c4d14ad266Subsidiarie97%

EX21:cbf2de40ee5aEX21:cbf2de40ee5aSubsidiarie97%

EX21:dcb988d78d06EX21:dcb988d78d06Subsidiarie97%

EX21:ead63bb1832aEX21:ead63bb1832aSubsidiarie97%

EX21:ec18fffe027eEX21:ec18fffe027eSubsidiarie97%

EX21:f41e86ce6042EX21:f41e86ce6042Subsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs IBRX · multiples and returns

KLAR—

KLAR.ST

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BNTX—

Biontech SE

$92,25

23,3B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

EXEL—

Exelixis Inc

$55,06

14,7B USD

P/E

19,5x

— vs self

Div yield

—

— vs self

ROE

40,4 %

-29,8 vs self

MDGL—

Madrigal Pharmaceuticals Inc

$482,00

11,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-47,8 %

-118,0 vs self

INSM—

Insmed Inc

$107,46

23,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-160,2 %

-230,4 vs self

VCYT—

Veracyte Inc

$45,30

3,6B USD

P/E

55,5x

— vs self

Div yield

—

— vs self

ROE

5,1 %

-65,1 vs self

MDXG—

Mimedx Group Inc

$4,27

636,0M USD

P/E

11,1x

— vs self

Div yield

—

— vs self

ROE

18,9 %

-51,3 vs self

AVIR—

Atea Pharmaceuticals Inc

$4,61

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

-57,5 %

-127,7 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,26

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-06 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,26
Revenue	—no estimate	—no estimate	209,5M USD
Operating income	—no estimate	—no estimate	-205,8M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution5 analysts

Strong buy2

Buy3

Hold0

Sell0

Strong sell0

12-month price target$14,80 · Median $13,00

Low $11,00High $23,00

Operating income · consensus-205,8M USD

EPS surprise

−47,3 %

reported vs consensus · miss

Revenue surprise

−45,9 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$11,00

Mean$14,80

Median$13,00

High$23,00

Spot$7,41

+99.7 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-226,0 %Above median

Net Margin-310,2 %Below median

ROE70,2 %Best in class

Capex / Rev-3,8 %Below median

D/E-1,61Best in class

Cash Conv0,87Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 587 948 sh14 exercises · 7 grants11 insiders

Selecky ChristobelDirector · Stock Option (right to buy) → Common StockAcquired 65 600 @ $7,25grant · 2026-06-09
Clark WesleyDirector · Stock Option (right to buy) → Common StockAcquired 65 600 @ $7,25grant · 2026-06-09
MAXWELL LINDADirector · Stock Option (right to buy) → Common StockAcquired 65 600 @ $7,25grant · 2026-06-09
Wendel BruceDirector · Stock Option (right to buy) → Common StockAcquired 65 600 @ $7,25grant · 2026-06-09
BLASZYK MICHAEL DDirector · Stock Option (right to buy) → Common StockAcquired 65 600 @ $7,25grant · 2026-06-09
Cohen CherylDirector · Stock Option (right to buy) → Common StockAcquired 65 600 @ $7,25grant · 2026-06-09
SOON-SHIONG PATRICKDirector, See remarks, 10% owner · Second Amended and Restated Convertible Promissory Note → Common StockDisposed — @ $5,43conversion · 2026-03-31
Selecky ChristobelDirector · Stock Option (right to buy) → Common StockDisposed 25 000 @ $2,98exercise · 2026-02-23
Adcock RichardDirector, CEO & President · Restricted Stock Units → Common StockDisposed 152 439exercise · 2026-02-22
Simon Barry J.Director · Restricted Stock Units → Common StockDisposed 15 243exercise · 2026-02-22
LAUER REGAN JChief Accounting Officer · Restricted Stock Units → Common StockDisposed 4 065exercise · 2026-02-22
Sachs David C.Chief Financial Officer · Restricted Stock Units → Common StockDisposed 40 650exercise · 2026-02-22
SOON-SHIONG PATRICKDirector, See remarks, 10% owner · Restricted Stock Units → Common StockDisposed 114 329exercise · 2026-02-22
LAUER REGAN JChief Accounting Officer · Restricted Stock Units → Common StockDisposed 5 482exercise · 2026-02-10
Sachs David C.Chief Financial Officer · Restricted Stock Units → Common StockDisposed 82 236exercise · 2026-02-10
SOON-SHIONG PATRICKDirector, See remarks, 10% owner · Restricted Stock Units → Common StockDisposed 274 122exercise · 2026-02-10
Adcock RichardDirector, CEO & President · Restricted Stock Units → Common StockDisposed 274 122exercise · 2026-02-10
Selecky ChristobelDirector · Stock Option (right to buy) → Common StockDisposed 25 000 @ $2,98exercise · 2026-01-20
Selecky ChristobelDirector · Stock Option (right to buy) → Common StockDisposed 50 000 @ $2,98exercise · 2026-01-16
Adcock RichardDirector, CEO & President · Restricted Stock Units → Common StockDisposed 34 483exercise · 2025-12-31
Sachs David C.Chief Financial Officer · Restricted Stock Units → Common StockDisposed 30 397exercise · 2025-12-31
Wendel BruceDirector · Stock Option (right to buy) → Common StockAcquired 146 020 @ $2,36grant · 2025-12-12

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

IBRX.O Market data — financials · 2026-05-28
Immunitybio Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$136M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$23M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$62M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$25M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$19M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$19M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$31M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$7M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$72M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$6M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$65M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$4M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$3M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$4M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$2M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$0M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

Leadership

Richard AdcockPresident, Chief Executive Officer, Director

Insider activity

Net selling0 buys · 9 sellsnet -$4,6M6 insiders · last 365d

Simon Barry J.Director · Common StockSold 23 033 @ $7,18$165K · 2026-06-04
SOON-SHIONG PATRICKDirector, See remarks, 10% owner · Common StockOther 4 606 596 @ $5,43$25,0M · 2026-03-31
Simon Barry J.Director · Common StockSold 75 000 @ $12,01$901K · 2026-02-24
Selecky ChristobelDirector · Common StockSold 25 000 @ $10,00$250K · 2026-02-23
Selecky ChristobelDirector · Common StockOther 25 000 @ $2,98$74K · 2026-02-23
Simon Barry J.Director · Common StockSold 165 000 @ $10,25$1,7M · 2026-02-23
LAUER REGAN JChief Accounting Officer · Common StockOther 4 065 · 2026-02-22
SOON-SHIONG PATRICKDirector, See remarks, 10% owner · Common StockOther 58 170 @ $8,70$506K · 2026-02-22
Sachs David C.Chief Financial Officer · Common StockOther 40 650 · 2026-02-22
Sachs David C.Chief Financial Officer · Common StockOther 20 682 @ $8,70$180K · 2026-02-22
SOON-SHIONG PATRICKDirector, See remarks, 10% owner · Common StockOther 114 329 · 2026-02-22
LAUER REGAN JChief Accounting Officer · Common StockOther 1 673 @ $8,70$15K · 2026-02-22
Adcock RichardDirector, CEO & President · Common StockOther 152 439 · 2026-02-22
Adcock RichardDirector, CEO & President · Common StockOther 77 560 @ $8,70$675K · 2026-02-22
Simon Barry J.Director · Common StockOther 15 243 · 2026-02-22
Simon Barry J.Director · Common StockOther 6 026 @ $8,70$52K · 2026-02-22
Simon Barry J.Director · Common StockSold 10 000 @ $9,25$92K · 2026-02-20
Sachs David C.Chief Financial Officer · Common StockOther 42 643 @ $6,93$296K · 2026-02-10
SOON-SHIONG PATRICKDirector, See remarks, 10% owner · Common StockOther 118 560 @ $6,93$822K · 2026-02-10
LAUER REGAN JChief Accounting Officer · Common StockOther 5 482 · 2026-02-10
SOON-SHIONG PATRICKDirector, See remarks, 10% owner · Common StockOther 274 122 · 2026-02-10
LAUER REGAN JChief Accounting Officer · Common StockOther 2 257 @ $6,93$16K · 2026-02-10
Adcock RichardDirector, CEO & President · Common StockOther 274 122 · 2026-02-10
Adcock RichardDirector, CEO & President · Common StockOther 140 048 @ $6,93$971K · 2026-02-10
Sachs David C.Chief Financial Officer · Common StockOther 82 236 · 2026-02-10

Short positioning

134.4Mshares short+1.9% vs prior

11.92days to cover

59.9%short of daily vol

36.7Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

IBRX.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Return on equity (FY 2025-12-31): 70.2%Derived (calculated)
Net margin (FY 2025-12-31): -310.3%Derived (calculated)
Return on assets (FY 2025-12-31): -70.0%Derived (calculated)
Current ratio (FY 2025-12-31): 5.10xDerived (calculated)
Debt-to-equity (FY 2025-12-31): -2.00xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -44.2%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -38.4%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 35.6%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 38.7%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 15.0%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 22.1%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 25.6%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 668.3%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -2.3%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 31.1%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 15.0%Derived (calculated)
Capex (annual): USD 3.85MSEC XBRL filing
Shares outstanding (annual): 1.01BSEC XBRL filing
Revenue (annual): USD 113.29MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
Pre-tax income (annual): USD -351.61MSEC XBRL filing
Operating income (annual): USD -256.03MSEC XBRL filing
Cost of revenue (annual): USD 753KSEC XBRL filing
Total assets (annual): USD 501.9MSEC XBRL filing

Showing 24 of 57 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-10FILING8-K filing →

2026-06-09 00:00 UTCINSIDER7 insider transactions — 2026-06 · net sell $165k 6 derivative

2026-06-09INSIDERClark Wesley acquired 65.6k sh Stock Option (right to buy) — Director

2026-06-09INSIDERSelecky Christobel acquired 65.6k sh Stock Option (right to buy) — Director

2026-06-09INSIDERBLASZYK MICHAEL D acquired 65.6k sh Stock Option (right to buy) — Director

2026-06-09INSIDERCohen Cheryl acquired 65.6k sh Stock Option (right to buy) — Director

2026-06-09INSIDERMAXWELL LINDA acquired 65.6k sh Stock Option (right to buy) — Director

2026-06-09INSIDERWendel Bruce acquired 65.6k sh Stock Option (right to buy) — Director

2026-06-04INSIDERSimon Barry J. sold 23.0k sh — Director ~$165k

2026-05-18FILING8-K filing →

2026-05-07FILING10-Q filing →

2026-05-07FILING8-K filing →

2026-04-30FILINGDEF 14A filing →

2026-04-09FILING8-K filing →

2026-04-06FILING8-K filing →

2026-03-31 00:00 UTCINSIDER2 insider transactions — 2026-03 · net buy $25.0M 1 derivative

2026-03-31FILING8-K filing →

2026-03-31INSIDERSOON-SHIONG PATRICK transacted 4.61M sh — Director, See remarks, 10% owner ~$25.00M

2026-03-31INSIDERSOON-SHIONG PATRICK disposed of — Director, See remarks, 10% owner

2026-02-24 00:00 UTCINSIDER33 insider transactions — 2026-02 · net sell $6.4M 10 derivative

2026-02-24INSIDERSimon Barry J. sold 75.0k sh — Director ~$901k

2026-02-23FILING10-K filing →

2026-02-23FILING8-K filing →

2026-02-23INSIDERSelecky Christobel sold 25.0k sh — Director ~$250k

2026-02-23INSIDERSelecky Christobel transacted 25.0k sh — Director ~$74k

2026-02-23INSIDERSimon Barry J. sold 165.0k sh — Director ~$1.69M

2026-02-23INSIDERSelecky Christobel disposed of 25.0k sh Stock Option (right to buy) — Director

2026-02-22INSIDERLAUER REGAN J transacted 4.1k sh — Chief Accounting Officer

2026-02-22INSIDERSOON-SHIONG PATRICK transacted 58.2k sh — Director, See remarks, 10% owner ~$506k

2026-02-22INSIDERSachs David C. transacted 40.6k sh — Chief Financial Officer

2026-02-22INSIDERSachs David C. transacted 20.7k sh — Chief Financial Officer ~$180k

2026-02-22INSIDERSOON-SHIONG PATRICK transacted 114.3k sh — Director, See remarks, 10% owner

2026-02-22INSIDERLAUER REGAN J transacted 1.7k sh — Chief Accounting Officer ~$15k

2026-02-22INSIDERAdcock Richard transacted 152.4k sh — Director, CEO & President

2026-02-22INSIDERAdcock Richard transacted 77.6k sh — Director, CEO & President ~$675k

Showing the 40 most recent of 62 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread